U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov. (Comparative Effectiveness Reviews, No. 76.)

Cover of Treatment for Hepatitis C Virus Infection in Adults

Treatment for Hepatitis C Virus Infection in Adults [Internet].

Show details

Appendix DExcluded Studies List

  1. Abergel A, Achim A, Kain I, et al. Efficacy of interferon (standard or pegylated) plus ribavirin in naive patients with hepatitis C virus genotype 5. A french multicenter study. Hepatology. 2011:817A. Exclusion Reason - Wrong Population.
  2. Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED). Exclusion Reason -Wrong Population.
  3. Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)(COMPLETED). Exclusion Reason - Wrong Population.
  4. Adiwijaya BS, Hare B, Caron PR, et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antiviral Therapy. 2009;14(4):591–5. Exclusion Reason -Wrong Study Design. [PubMed: 19578245]
  5. Adiwijaya B, Herrmann E, Hare B, et al. A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants. PLoS Comput Biol. 2010;6(4):e1000745. Exclusion Reason -Not Relevant. [PMC free article: PMC2855330] [PubMed: 20419154]
  6. Adiwijaya BS, Kieffer TL, Henshaw J, et al. A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection. PLoS Comput Biol. 2012;8(1):e1002339–e1002339. Exclusion Reason -Not Relevant. [PMC free article: PMC3252270] [PubMed: 22241977]
  7. Adiwijaya BS, Kieffer TL, Henshaw J, et al. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis c infection. PLoS Computational Biology. 2012;8(1) Exclusion Reason - Background. [PMC free article: PMC3252270] [PubMed: 22241977]
  8. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004 May;126(5):1302–11. Exclusion Reason -Not Relevant. [PubMed: 15131791]
  9. Ahn, Flamm Boceprevir versus telaprevir: A new era of directly acting antiviral therapy. Current Hepatitis Reports. 2012;11(1):23–33. Exclusion Reason – Background.
  10. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52(2):421–429. Exclusion Reason -Wrong Study Design. [PubMed: 20648473]
  11. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. Journal of Medical Virology. 2010;82(4):575–582. Exclusion Reason -Wrong Study Design. [PubMed: 20166188]
  12. Akuta N, Suzuki F, Suzuki Y, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scandinavian Journal of Gastroenterology. 2005 Jun;40(6):688–96. Exclusion Reason -Wrong Drug. [PubMed: 16036529]
  13. Alavian SM, Behnava B, Tabatabaei SV, et al. Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. Pharmacol Clin. 2010;66(11):1071–1071. Exclusion Reason -Wrong Drug. [PubMed: 20857094]
  14. Alavian SM, Jabbari H, Daryani NE. Hepatitis Monthly; Hepatitis C virus the rising concerns and growing hopes, report from the HCV symposium, fourth Tehran Hepatitis Congress; November 2011; Tehran, Iran. 2012. pp. 107–113. Exclusion Reason - Background.
  15. Alsiö A, Rembeck K, Askarieh G, et al. Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis c genotype 2 or 3. PLoS ONE [Electronic Resource] 2012;7(5) Exclusion Reason – Background. [PMC free article: PMC3360051] [PubMed: 22655053]
  16. Alvarez-Uria G, Day JN, Nasir AJ, et al. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver International. 2009 Aug;29(7):1051–5. Exclusion Reason -Not Relevant. [PubMed: 19580634]
  17. Amarapurkar DN, Patel ND, Rane P, et al. Do different hepatitis C virus genotypes behave differently? Tropical Gastroenterology. 2007 Jul–Sep;28(3):99–104. Exclusion Reason -Not Relevant. [PubMed: 18383996]
  18. Andersen ES, Moessner BK, Christensen PB, et al. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. European Journal of Gastroenterology & Hepatology. 2011 Jan;23(1):41–4. Exclusion Reason -Not Relevant. [PubMed: 21079513]
  19. Angelico M, Koehler-Horst B, Piccolo P, et al. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C. European Journal of Gastroenterology & Hepatology. 2008 Jul;20(7):680–7. Exclusion Reason -Not Relevant. [PubMed: 18679072]
  20. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. Journal of Hepatology. 2007 Jun;46(6):1009–17. Exclusion Reason -Not Relevant. [PubMed: 17328985]
  21. Arase Y, Suzuki F, Akuta N, et al. Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load. Internal Medicine. 2009;48(5):253–8. Exclusion Reason -Not Relevant. [PubMed: 19252344]
  22. Arase Y, Suzuki F, Sezaki H, et al. Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intervirology. 2008;51(1):1–6. Exclusion Reason -Not Relevant. [PubMed: 18309242]
  23. Arase Y, Suzuki F, Suzuki Y, et al. Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Internal Medicine. 2007;46(22):1827–32. Exclusion Reason -Not Relevant. [PubMed: 18025763]
  24. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010 Aug;52(2):518–27. Exclusion Reason -Not Relevant. [PubMed: 20683951]
  25. Asselah T. A revolution in HCV treatment with direct-acting antivirals: From non-response to eradication. Journal of Hepatology. 2012;57(2):455–457. Exclusion Reason - Background. [PubMed: 22465738]
  26. Awad T, Brok J, Thorlund K, et al. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C. Cochrane Database of Systematic Reviews. 2009;(1) Exclusion Reason – Background.
  27. Awad T, Thorlund K, Hauser G, et al. Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C. Cochrane Database of Systematic Reviews. 2009;(1) Exclusion Reason - Background.
  28. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials. Hepatology. 2010;51(4):1176–1184. Exclusion Reason -Not Relevant. [PubMed: 20187106]
  29. Ayaz C, Celen MK, Yuce UN, et al. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World Journal of Gastroenterology. 2008 Jan 14;14(2):255–9. Exclusion Reason -Wrong Population. [PMC free article: PMC2675123] [PubMed: 18186564]
  30. Backus LI, Boothroyd DB, Phillips BR, et al. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. Journal of Viral Hepatitis. 2006 Dec;13(12):799–810. Exclusion Reason -Wrong Outcome. [PubMed: 17109679]
  31. Bacon BR, Khalid O. Triple therapy with boceprevir for HCV genotype 1 infection: Phase III results in relapsers and nonresponders. Liver International. 2012;32(SUPPL 1):51–53. Exclusion Reason - Background. [PubMed: 22212572]
  32. Bain VG, Lee SS, Peltekian K, et al. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Alimentary Pharmacology & Therapeutics. 2008 Jul;28(1):43–50. Exclusion Reason -Not Relevant. [PubMed: 18397386]
  33. Balon R. Clinical factor 2011. Psychotherapy and Psychosomatics. 2012;81(4):199–205. Exclusion Reason - Background. [PubMed: 22585011]
  34. Barbotte L, Ahmed-Belkacem A, Chevaliez S, et al. Characterization of V36C, a Novel Amino Acid Substitution Conferring Hepatitis C Virus (HCV) Resistance to Telaprevir, a Potent Peptidomimetic Inhibitor of HCV Protease. Antimicrobial Agents and Chemotherapy. 2010 June;54(6):2681–2683. 2010. Exclusion Reason - Wrong Outcomes. [PMC free article: PMC2876365] [PubMed: 20368394]
  35. Barritt Iv AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology. 2012;142(6):1314–1323.e1. Exclusion Reason - Background. [PMC free article: PMC3683992] [PubMed: 22537438]
  36. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment-Naive Subjects. Journal of Infectious Diseases. 2008 September 15;198(6):800–807. 2008. Exclusion Reason -Wrong Study Design. [PubMed: 18637752]
  37. Berak. Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2a vs alfa 2b treatment of patients with chronic hepatitis C infected with non 2/3 genotypes – 12 week virological response analysis. Hepatology. 2005;42(Suppl 1):1. Exclusion Reason - Wrong Drug.
  38. Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin. Exclusion Reason - Wrong Population.
  39. Bognar F. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: Subgroup analysis of SPRINT-2 and RESPOND-2 Studies. Journal of Gastroenterology and Hepatology. 2011;26:93. Exclusion Reason - Wrong Population.
  40. Bognar F. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. Journal of Gastroenterology and Hepatology. 2011:19–20. Exclusion Reason - Wrong Population.
  41. Bognar F. Projecting the clinical impact of therapeutic regimens including boceprevir in previously untreated adult subjects with chronic hepatitis C genotype 1. Journal of Gastroenterology and Hepatology. 2011;19 Exclusion Reason - Wrong Population.
  42. Bonner JB, Barret AS, Fried FW, et al. Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. Digestive Diseases & Sciences. 2012 Jun;57(6):1439–44. Exclusion Reason - Background. [PMC free article: PMC3683984] [PubMed: 22488633]
  43. Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. Journal of Hepatology. 2007 Mar;46(3):420–31. Exclusion Reason -Not Relevant. [PMC free article: PMC1995129] [PubMed: 17196293]
  44. Bonkovsky HL, Tice AD, Yapp RG, et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. American Journal of Gastroenterology. 2008 Nov;103(11):2757–65. Exclusion Reason -Not Relevant. [PubMed: 18684176]
  45. Borroni G, Andreoletti M, Casiraghi MA, et al. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection. Alimentary Pharmacology & Therapeutics. 2008 May;27(9):790–7. Exclusion Reason -Not Relevant. [PubMed: 18298638]
  46. Bourlière M, Ouzan D, Rosenheim M, et al. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: The Hepatys French cohort (2003–2007). Antiviral Therapy. 2012;17(1):101–110. Exclusion Reason – Background. [PubMed: 22267474]
  47. Brandman D, Bacchetti P, Ayala CE, et al. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012;35(5):1090–1094. Exclusion Reason – Background. [PMC free article: PMC3329815] [PubMed: 22399695]
  48. Brennan BJ, Morcos PN, Wang K, et al. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2012 May;35(10):1209–20. Exclusion Reason - Wrong Outcomes. [PubMed: 22469033]
  49. Brok J, Gluud LL, Gluud C, et al. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database of Systematic Reviews. 2009;(1) Exclusion Reason – Background. [PubMed: 19821346]
  50. Brok J, Gluud LL, Gluud C, et al. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews. 2010;(5) Exclusion Reason - Background. [PubMed: 20091577]
  51. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antiviral Therapy. 2004;9(4):491–497. Exclusion Reason -Wrong Outcome. [PubMed: 15456079]
  52. Bruno R, Sacchi P, Cima S, et al. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. Journal of Viral Hepatitis. 2012;19(1):33–36. Exclusion Reason - Wrong Outcomes. [PubMed: 22233411]
  53. Bühler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver International. 2012;32(1):9–16. Exclusion Reason – Background. [PubMed: 22212566]
  54. Burton MJ, Passarella MJ, McGuire BM. Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: Implications for patients and providers. Southern Medical Journal. 2012;105(8):431–436. Exclusion Reason - Wrong Study Design. [PubMed: 22864102]
  55. Calès P, Zarski JP, Marc Chapplain J, et al. Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry. Journal of Viral Hepatitis. 2012;19(2):e143–e153. Exclusion Reason – Background. [PubMed: 22239512]
  56. Carruthers SJ. Hepatitis C treatment and injecting drug users in Perth, Western Australia: Knowledge of personal status and eligibility criteria for treatment. Journal of Substance Use. 2012 Feb;17(1):32–40. Exclusion Reason – Background.
  57. Casey LC, Lee WM. Hepatitis C therapy update. Current Opinion in Gastroenterology. 2012;28(3):188–192. Exclusion Reason - Background. [PubMed: 22476156]
  58. Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090–101. Exclusion Reason – Background. [PubMed: 21745274]
  59. Chang CH, Chen KY, Lai MY, et al. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2002 Sep;16(9):1623–32. Exclusion Reason -Not Relevant. [PubMed: 12197841]
  60. Charlebois A, Lee L, Cooper E, et al. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. Journal of Viral Hepatitis. 2012. Exclusion Reason - Background. [PubMed: 23121361]
  61. Chavalitdhamrong D, Tanwandee T. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World Journal of Gastroenterology. 2006 Sep 14;12(34):5532–5. Exclusion Reason -Wrong Drug. [PMC free article: PMC4088239] [PubMed: 17006994]
  62. Chayama K, Hayes CN, Abe H, et al. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C. Journal of Infectious Diseases. 2011 July 1;204(1):84–93. 2011. Exclusion Reason -Wrong Outcomes. [PMC free article: PMC3307155] [PubMed: 21628662]
  63. Chen L-j, Li M-h, Xie Y, et al. Effect of hepatitis C virus serotype on the response of patients with chronic hepatitis C to interferon treatment. Chinese Journal of Experimental & Clinical Virology. 2007 Jun;21(2):117–9. Exclusion Reason -Not Relevant. [PubMed: 17653309]
  64. Chen T-M, Huang P-T, Lin C-H, et al. Feasibility of individualized treatment for hepatitis C patients in the real world. Journal of Gastroenterology & Hepatology. 2010 Jan;25(1):61–9. Exclusion Reason -Not Relevant. [PubMed: 19780879]
  65. Chen W-l, Chen X-p, Chen X-f, et al. Individualized respond guidance treatment of chronic hepatitis C with combination of peginterferon -2a and ribavirin. Chung Hua Kan Tsang Ping Tsa Chih. 2010 Aug;18(8):585–9. Exclusion Reason -Not Relevant. [PubMed: 20825712]
  66. Cheng WSC, Roberts SK, McCaughan G, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology. 2010 Oct;53(4):616–23. Exclusion Reason -Not Relevant. [PubMed: 20619475]
  67. Chevaliez S, Hézode C, Pawlotsky JM. Antiviral strategies in hepatitis C infection. [Stratégies antivirales dans l'hépatite chronique C]. 2012;14(2):78–88. Exclusion Reason – Background.
  68. Chu TW, Kulkarni R, Gane EJ, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology. 2012;142(4):790–795. Exclusion Reason - Background. [PubMed: 22248659]
  69. Ciancio A, Picciotto A, Giordanino C, et al. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology & Therapeutics. 2006 Oct 1;24(7):1079–86. Exclusion Reason -Not Relevant. [PubMed: 16984502]
  70. Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C. 2010. Exclusion Reason - Background.
  71. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004 Dec;40(6):1260–5. Exclusion Reason -Not Relevant. [PubMed: 15558712]
  72. Dalgard O, Bjoro K, Ring-Larsen H, et al. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. European Journal of Gastroenterology & Hepatology. 2010 May;22(5):552–6. Exclusion Reason -Not Relevant. [PubMed: 20154627]
  73. Dan AA, Crone C, Wise TN, et al. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics. 2007 May–Jun;48(3):223–9. Exclusion Reason -Not Relevant. [PubMed: 17478591]
  74. Daw MA, Dau AA. Hepatitis C virus in Arab world: A state of concern. The Scientific World Journal. 2012. 2012. Exclusion Reason – Background. [PMC free article: PMC3354686] [PubMed: 22629189]
  75. De Azevedo FKSF, de Azevedo CCSF, Souto FJD. Souto. Assessment of the treatment of chronic hepatitis C in the state of mato grosso, central Brazil. Memorias do Instituto Oswaldo Cruz. 2012;107(2):117–123. Exclusion Reason - Background. [PubMed: 22415261]
  76. de Bruijne J, Bergmann JF, Reesink HW, et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology. 2010 Nov;52(5):1590–9. Exclusion Reason -Not Relevant. [PubMed: 20938912]
  77. De Bruijne J, Van Vliet A, Weegink CJ, et al. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: A novel macrocyclic HCV protease inhibitor. Antiviral Therapy. 2012;17(4):633–642. Exclusion Reason - Background. [PubMed: 22427481]
  78. De Rosa FG, Bargiacchi O, Audagnotto S, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. Journal of Antimicrobial Chemotherapy. 2006 Feb;57(2):360–3. Exclusion Reason -Not Relevant. [PubMed: 16396921]
  79. De-Rueda PM, Ruiz-Extremera A, Candel JM, et al. Plasma Ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients. Journal of Clinical Gastroenterology. 2012;46(4):328–333. Exclusion Reason - Background. [PubMed: 22105181]
  80. Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World Journal of Gastroenterology. 2006 Sep 21;12(35):5692–8. Exclusion Reason -Not Relevant. [PMC free article: PMC4088172] [PubMed: 17007024]
  81. Desai TK, Bortman J, Al-Sibae R, et al. The role of iron in hepatitis C infection. Current Hepatitis Reports. 2012;11(1):41–47. Exclusion Reason - Background.
  82. Di Bisceglie AM, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis. 2007 Oct;14(10):721–9. Exclusion Reason -Not Relevant. [PubMed: 17875007]
  83. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. New England Journal of Medicine. 2008 Dec 4;359(23):2429–41. Exclusion Reason -Wrong Outcomes. [PMC free article: PMC2606037] [PubMed: 19052125]
  84. Di Bisceglie AM, Dusheiko GM, Muir AJ, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin: Analyses of pre-defined subpopulations in the phase 3 advance trial. Gastroenterology. 2011:S908. Exclusion Reason - Wrong Population.
  85. Diago M, Olveira A, Sola R, et al. Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate. Alimentary Pharmacology & Therapeutics. 2007 Apr 15;25(8):899–906. Exclusion Reason -Not Relevant. [PubMed: 17402993]
  86. Diago M, Shiffman ML, Bronowicki J-P, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology. 2010 Jun;51(6):1897–903. Exclusion Reason -Not Relevant. [PubMed: 20196118]
  87. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. American Journal of Gastroenterology. 2003 Nov;98(11):2491–9. Exclusion Reason -Not Relevant. [PubMed: 14638354]
  88. Druyts E, Mills EJ, Nachega J, et al. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: A meta-analysis. Clinical and Experimental Gastroenterology. 2012;5(1):11–21. Exclusion Reason - Wrong Population. [PMC free article: PMC3304330] [PubMed: 22427726]
  89. Ebner N, Wanner C, Winklbaur B, et al. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addiction Biology. 2009 Apr;14(2):227–37. Exclusion Reason -Not Relevant. [PubMed: 19291011]
  90. Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED). Exclusion Reason - Wrong Population.
  91. Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED). Exclusion Reason - Wrong Population.
  92. Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116). Exclusion Reason - Wrong Population.
  93. El-Serag HB, Mason AC. Rising Incidence of Hepatocellular Carcinoma in the United States. New England Journal of Medicine. 1999;340(10):745–50. Exclusion Reason – Background. [PubMed: 10072408]
  94. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Archives of Internal Medicine. 2000;160(21):3227–30. Exclusion Reason - Background. [PubMed: 11088082]
  95. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Annals of Internal Medecine. 2003;139(10):817–23. Exclusion Reason – Background. [PubMed: 14623619]
  96. El-Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. American Journal of Gastroenterology. 2005 Nov;100(11):2447–52. Exclusion Reason -Not Relevant. [PubMed: 16279899]
  97. Everhart JE, Lok AS, Kim H-Y, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009 Aug;137(2):549–57. Exclusion Reason -Not Relevant. [PMC free article: PMC3148692] [PubMed: 19445938]
  98. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Alimentary Pharmacology & Therapeutics. 2008 Apr 1;27(7):542–51. Exclusion Reason -Wrong Outcomes. [PubMed: 18208570]
  99. Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Alimentary Pharmacology & Therapeutics. 2009 Mar 1;29(5):589–601. Exclusion Reason -Not Relevant. [PMC free article: PMC3767280] [PubMed: 19053983]
  100. Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685AM3)(COMPLETED). Exclusion Reason - Wrong Population.
  101. Fabrizi F, Dixit V, Messa P, et al. Interferon therapy of acute hepatitis c in dialysis patients: Meta-analysis. Journal of Viral Hepatitis. 2012. Exclusion Reason – Background. [PubMed: 23043385]
  102. Fabrizi F, Dixit V, Messa P, et al. Hepatitis C-related liver disease in dialysis patients. 2012;176:42–53. Exclusion Reason - Background. [PubMed: 22310780]
  103. Falasca K, Mancino P, Ucciferri C, et al. Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy. Clinical & Investigative Medicine - Medecine Clinique et Experimentale. 2009;32(3):E212–8. Exclusion Reason -Not Relevant. [PubMed: 19480737]
  104. Fartoux L, Degos F, Trepo C, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clinical Gastroenterology & Hepatology. 2007 Apr;5(4):502–7. Exclusion Reason -Not Relevant. [PubMed: 17261383]
  105. Feld JJ. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals? Gastroenterology. 2012;142(6):1356–1359. Exclusion Reason - Background. [PubMed: 22537443]
  106. Ferenci P, Laferl H, Scherzer T-M, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008 Aug;135(2):451–8. Exclusion Reason -Not Relevant. [PubMed: 18503773]
  107. Ferenci P. Optimal treatment duration for patients with HCV genotype 1 infection. Journal of Viral Hepatitis. 2012;19(SUPPL 1):7–13. Exclusion Reason – Background. [PubMed: 22233408]
  108. Ferenci P. Treatment of chronic hepatitis C - are interferons really necessary? Liver International. 2012;32(SUPPL 1):108–112. Exclusion Reason - Background. [PubMed: 22212580]
  109. Fernández-Rodríguez CM, Alonso S, Martinez SM, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. American Journal of Gastroenterology. 2010 Oct;105(10):2164–72. [Erratum appears in Am J Gastroenterol. 2010 Oct;105(10):2308] quiz 2173. Exclusion Reason -Not Relevant. [PubMed: 20700116]
  110. Feuerstadt P, Bunim AL, Garcia H, et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology. 2010 Apr;51(4):1137–43. Exclusion Reason -Not Relevant. [PubMed: 20049907]
  111. Flamm S, Lawitz, Jacobson I, et al. High Sustained Virologic Response Among Genotype 1 Previous Non-responders and Relapsers to Peginterferon/Ribavirin when Re-treated With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin. 2011. Exclusion Reason - Wrong Population.
  112. Floreani, et al. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis. Journal of Clinical Gastroenterology. 2008 Jul;42(6):734–7. Exclusion Reason -Not Relevant. [PubMed: 18285717]
  113. Fonseca-Coronado S, Escobar-Gutierrez A, Ruiz-Tovar K, et al. Specific Detection of Naturally Occurring Telaprevir and Boceprevir (Protease Inhibitors) HCV Resistant Mutants among Treatment Naïve Infected Individuals. Journal of Clinical Microbiology. 2011 November 23 2011. Exclusion Reason -Wrong Outcomes. [PMC free article: PMC3264164] [PubMed: 22116161]
  114. Fontana RJ, Bieliauskas LA, Back-Madruga C, et al. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C. American Journal of Gastroenterology. 2010 Jul;105(7):1551–60. Exclusion Reason -Not Relevant. [PMC free article: PMC3772520] [PubMed: 20104219]
  115. Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology. 2007 May;45(5):1154–63. Exclusion Reason -Not Relevant. [PubMed: 17465000]
  116. Fontana RJ, Sanyal AJ, Ghany MG, et al. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology. 2010 Jun;138(7):2321–31. 2010. Exclusion Reason -Not Relevant. [PMC free article: PMC2883673] [PubMed: 20211180]
  117. Fontanges T, Beorchia S, Douvin C, et al. Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection. Gastroenterologie Clinique et Biologique. 2007 Jun–Jul;31(6–7):566–72. Exclusion Reason -Not Relevant. [PubMed: 17646782]
  118. Ford N, Kirby C, Singh K, et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: A systematic review and meta-analysis. Bulletin of the World Health Organization. 2012;90(7):540–550. Exclusion Reason - Background. [PMC free article: PMC3397704] [PubMed: 22807600]
  119. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007 Sep;46(3):640–8. Exclusion Reason -Not Relevant. [PubMed: 17879366]
  120. Forestier N, Zeuzem S. Telaprevir for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy. 2012;13(4):593–606. Exclusion Reason - Background. [PubMed: 22332992]
  121. Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. Journal of Viral Hepatitis. 2003 Jul;10(4):271–6. Exclusion Reason -Not Relevant. [PubMed: 12823593]
  122. Foster GR, Fried MW, Hadziyannis SJ, et al. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scandinavian Journal of Gastroenterology. 2007 Feb;42(2):247–55. Exclusion Reason -Not Relevant. [PubMed: 17327945]
  123. Foster GR, Hezode C, Bronowicki J, et al. Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections. Gastroenterology. 2011;141(3):881–889.e1. Exclusion Reason -Wrong Outcomes. [PubMed: 21699786]
  124. Fuster D, Planas R, Gonzalez J, et al. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antiviral Therapy. 2006;11(4):473–82. [Erratum appears in Antivir Ther. 2006;11(5):667] Exclusion Reason -Not Relevant. [PubMed: 16856621]
  125. Gaetano JN, Desai AP, Reau N, et al. The era of direct-acting antivirals: The evolving role of interferon and ribavirin for the treatment of chronic hepatitis C. Clinical Medicine Insights: Therapeutics. 2012;4:39–56. Exclusion Reason - Background.
  126. Gane EJ, Roberts SK, Stedman CAM, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010 Oct 30;376(9751):1467–75. Exclusion Reason -Not Relevant. [PubMed: 20951424]
  127. Garg V, Chandorkar G, Farmer HF, et al. Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin. The Journal of Clinical Pharmacology. 2011 December 12 2011. Exclusion Reason -Wrong Study Design. [PubMed: 22162542]
  128. Garg V, van Heeswijk R, Eun Lee J, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54(1):20–27. Exclusion Reason -Wrong Study Design. [PubMed: 21618566]
  129. Garg V, van Heeswijk R, Yang Y, et al. The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir. J Clin Pharmacol. 2011. Exclusion Reason -Wrong Study Design. [PubMed: 22039291]
  130. Geitmann M, Dahl G, Danielson UH. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors. Journal of Molecular Recognition. 2011;24(1):60–70. Exclusion Reason -Not Relevant. [PubMed: 21194118]
  131. Gheorghe L, Iacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. Journal of Gastrointestinal & Liver Diseases. 2007 Mar;16(1):23–9. Exclusion Reason -Not Relevant. [PubMed: 17410285]
  132. Giannini E, Fasoli A, Botta F, et al. Long-term follow up of chronic hepatitis C patients after α-interferon treatment: A functional study. Journal of Gastroenterology and Hepatology. 2001;16(4):399–405. Exclusion Reason -Wrong Drug. [PubMed: 11354278]
  133. Giannini EG, Marenco S, Fazio V, et al. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver International. 2012;32(7):1113–1119. Exclusion Reason - Background. [PubMed: 22471814]
  134. Girolomoni G, Altomare G, Ayala F, et al. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacology and Immunotoxicology. 2012;34(4):548–560. Exclusion Reason - Background. [PubMed: 22296031]
  135. Gish RG, Arora S, Rajender Reddy K, et al. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. Journal of Hepatology. 2007 Jul;47(1):51–9. Exclusion Reason -Not Relevant. [PubMed: 17470380]
  136. Gluud LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews. 2009;(1) Exclusion Reason - Background. [PubMed: 17636700]
  137. Gonçalves CBT, Amaral KM, Sander GB, et al. Effectiveness of alpha interferon (+ ribavirin) in the treatment of chronic viral hepatitis C genotypes 2 and 3 in a brazilian sample. [Efetividade da alfainterferona (+ribavirina) no tratamento da hepatite viral crônica C genótipos 2 e 3 em amostra brasileira]. 2012;49(2):150–156. Exclusion Reason - Background. [PubMed: 22767003]
  138. Goodman ZD, Stoddard AM, Bonkovsky HL, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology. 2009 Dec;50(6):1738–49. Exclusion Reason -Not Relevant. [PMC free article: PMC3707633] [PubMed: 19824074]
  139. Gramenzi A, Cursaro C, Margotti M, et al. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. World Journal of Gastroenterology. 2009 Dec 21;15(47):5946–52. Exclusion Reason -Not Relevant. [PMC free article: PMC2795181] [PubMed: 20014458]
  140. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. Journal of Gastroenterology & Hepatology. 2007 Sep;22(9):1519–25. Exclusion Reason -Not Relevant. [PubMed: 17645460]
  141. Grebely J, Pham ST, Matthews GV, et al. White. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2012;55(4):1058–1069. Exclusion Reason - Background. [PMC free article: PMC3310282] [PubMed: 22031335]
  142. Guedj J, Perelson A. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology (Baltimore, Md.). 2011;53(6):1801–8. Exclusion Reason -Wrong Outcomes. [PMC free article: PMC3103645] [PubMed: 21384401]
  143. Gupta R, Kim S, Taylor MW, et al. Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC). Journal of Translational Medicine. 2012;10(1) Exclusion Reason - Background. [PMC free article: PMC3342120] [PubMed: 22436241]
  144. Han Q, Liu Z, Kang W, et al. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial. Digestive Diseases & Sciences. 2008 Aug;53(8):2238–45. Exclusion Reason -Not Relevant. [PubMed: 18080763]
  145. Harrington PR, Zeng W, Naeger LK, et al. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology. 2011. Exclusion Reason -Wrong Outcomes. [PubMed: 22095516]
  146. Harrison SA, Hamzeh FM, Han J, et al. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012;56(2):464–473. Exclusion Reason - Background. [PubMed: 22334369]
  147. Hayashi K, Kumada T, Nakano S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy. Hepatogastroenterology. 2002;49(44):508–512. Exclusion Reason -Wrong Population. [PubMed: 11995484]
  148. Helbling B, Stamenic I, Viani F, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology. 2002 Feb;35(2):447–54. Exclusion Reason -Not Relevant. [PubMed: 11826422]
  149. Helsper CWa, Hellinga HLa, van Essen GAa, et al. Real-life costs of hepatitis C treatment. Netherlands Journal of Medicine. 2012;70(3):145–153. Exclusion Reason - Background. [PubMed: 22516582]
  150. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004 Nov;127(5):1347–55. Exclusion Reason -Not Relevant. [PubMed: 15521004]
  151. Ho RJY, Chien JY. Drug delivery trends in clinical trials and translational medicine: Growth in biologic molecule development and impact on rheumatoid arthritis, crohn's disease, and colitis. Journal of Pharmaceutical Sciences. 2012;101(8):2668–2674. Exclusion Reason – Background. [PMC free article: PMC4826476] [PubMed: 22573521]
  152. Hofmann WP, Zeuzem S. Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy. Nature Reviews Gastroenterology and Hepatology. 2012;9(2):67–68. Exclusion Reason - Background. [PubMed: 22183183]
  153. Horsmans Y, Colle I, Van Vlierberghe H, et al. Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection. Acta Gastroenterologica Belgica. 2008 Jul–Sep;71(3):293–7. Exclusion Reason -Not Relevant. [PubMed: 19198574]
  154. Hotho DM, De Bruijne J, O'Farrell AM, et al. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design. Antiviral Therapy. 2012;17(2):365–375. Exclusion Reason - Background. [PubMed: 22293533]
  155. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. Journal of Hepatology. 2007 Feb;46(2):206–12. Exclusion Reason -Not Relevant. [PubMed: 17125876]
  156. Iacobellis A, Perri F, Valvano MR, et al. Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology. 2011;9(3):249–53. Exclusion Reason - Wrong Population. [PubMed: 21092761]
  157. Ikeda K, Arase Y, Kobayashi M, et al. A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients. Digestive Diseases and Sciences. 2006;51(3):603–609. Exclusion Reason -Wrong Drug. [PubMed: 16614974]
  158. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. Journal of Gastroenterology. 2004 Nov;39(11):1069–77. Exclusion Reason -Not Relevant. [PubMed: 15580400]
  159. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology. 2011;53(4):1090–1099. Exclusion Reason -Wrong Outcomes. [PubMed: 21480315]
  160. Innes H, Hutchinson S, Allen S, et al. the Hepatitis C Clinical Database Monitoring Committee. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. European Journal of Gastroenterology & Hepatology. 2012 Jun;24(6):646–55. Exclusion Reason - Wrong Study Design. [PubMed: 22433796]
  161. Jacobson IM, Ahmed F, Russo MW, et al. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. American Journal of Gastroenterology. 2004 Sep;99(9):1700–5. [Erratum appears in Am J Gastroenterol. 2004 Oct;99(10):2075] Exclusion Reason -Not Relevant. [PubMed: 15330905]
  162. Jafferbhoy H, Miller MH, Dunbar JK, et al. Intravenous drug use: Not a barrier to achieving a sustained virological response in HCV infection. Journal of Viral Hepatitis. 2012;19(2):112–119. Exclusion Reason - Background. [PubMed: 22239500]
  163. Jee Eun JEL, Rolf RvH, Katia KA, et al. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. CORD Conference Proceedings. 2011;55(10):4569–4574. Exclusion Reason -Not Relevant. [PMC free article: PMC3187007] [PubMed: 21825288]
  164. Jeong S, Kawakami Y, Kitamoto M, et al. Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy. Journal of Gastroenterology & Hepatology. 2008 Apr;23(4):541–5. Exclusion Reason -Not Relevant. [PubMed: 18397484]
  165. Kabbaj N, Guedira MM, El Atmani H, et al. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Annales d Endocrinologie. 2006 Sep;67(4):343–7. Exclusion Reason -Not Relevant. [PubMed: 17072240]
  166. Kagawa T, Kojima SI, Shiraishi K, et al. Weight-based high- and low-dose ribavirin in combination with peginterferon α-2b therapy for genotype 2 chronic hepatitis C: A randomized trial. Hepatology Research. 2012;42(4):351–358. Exclusion Reason - Background. [PubMed: 22176474]
  167. Kaito M, Yasui-Kawamura N, Iwasa M, et al. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Hepato-Gastroenterology. 2003 May–Jun;50(51):775–8. Exclusion Reason -Not Relevant. [PubMed: 12828083]
  168. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. 2007 Dec;46(6):1732–40. Exclusion Reason -Not Relevant. [PubMed: 17943989]
  169. Kashiwagi K, Furusyo N, Kubo N, et al. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. Journal of Infection and Chemotherapy. 2003;9(4):333–340. Exclusion Reason - Wrong Drug. [PubMed: 14691655]
  170. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver International. 2010 Mar;30(3):447–54. Exclusion Reason -Not Relevant. [PubMed: 19919569]
  171. Kim JH, Han KH, Lee KS, et al. Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. Yonsei Med J. 2006;47(6):793–798. Exclusion Reason -Wrong Drug. [PMC free article: PMC2687818] [PubMed: 17191307]
  172. Kim KI, Sasase N, Taniguchi M, et al. Prediction of Efficacy of Interferon Treatment of Chronic Hepatitis C and Occurrence of HCC after Interferon Treatment by a New Classification. Intervirology. 2005;48(1):52–58. Exclusion Reason - Wrong Drug. [PubMed: 15785090]
  173. Kim TH, Kim KA, Lim YS, et al. Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy. Intervirology. 2005;48(4):230–8. Exclusion Reason -Not Relevant. [PubMed: 15920347]
  174. Kiser JJ, Burton JR, Anderson PL, et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55(5):1620–1628. Exclusion Reason – Background. [PMC free article: PMC3345276] [PubMed: 22331658]
  175. Klibanov OM, Vickery SB, Olin JL, et al. Boceprevir: A novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy. 2012;32(2):173–190. Exclusion Reason - Background. [PubMed: 22392426]
  176. Ko W-S, Guo C-H, Hsu G-SW, et al. The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin. Clinical Biochemistry. 2005 Jul;38(7):614–20. Exclusion Reason -Not Relevant. [PubMed: 15904908]
  177. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver International. 2007 Mar;27(2):186–91. Exclusion Reason -Wrong Outcomes. [PubMed: 17311612]
  178. Köse S, Senger SS, Ersan G, et al. Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C. Clinical and Experimental Nephrology. 2012:1–5. Exclusion Reason - Wrong study design. [PubMed: 22814955]
  179. Kozielewicz D, Halota W, Dybowska D, et al. Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively. Skuteczność terapii trójlekowej u chorych przewlekle zakazonych HCV, nieleczonych i z nieskuteczna wcześniejsza terapia. 2012;66(1):49–54. Exclusion Reason - Background. [PubMed: 22708298]
  180. Kramer JR, Davila JA, Duan Z, et al. Antiviral treatment for hepatitis C virus is associated with a reduced risk of hepatocellular carcinoma in a national cohort of U.S. veterans. Gastroenterology. 2011;140(5):899. Exclusion Reason - Wrong Population.
  181. Kramer JR, Kanwal F, Richardson P, et al. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. Journal of Hepatology. 2012;56(2):320–325. Exclusion Reason - Background. [PubMed: 21756855]
  182. Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. Journal of Clinical Psychiatry. 2003 Jun;64(6):708–14. Exclusion Reason -Not Relevant. [PubMed: 12823087]
  183. Kronenberger B, Berg T, Herrmann E, et al. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. European Journal of Gastroenterology & Hepatology. 2007 Aug;19(8):639–46. Exclusion Reason -Not Relevant. [PubMed: 17625432]
  184. Kronenberger B, Zeuzem S. Advances in the treatment of hepatitis C virus infection. Gastroenterology and Hepatology. 2012;8(2):91–101. Exclusion Reason – Background. [PMC free article: PMC3317517] [PubMed: 22485076]
  185. Kronenberger B, Zeuzem S. New developments in HCV therapy. Journal of Viral Hepatitis. 2012;19(SUPPL 1):48–51. Exclusion Reason - Background. [PubMed: 22233414]
  186. Kuboki M, Iino S, Okuno T, et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. Journal of Gastroenterology & Hepatology. 2007 May;22(5):645–52. [Erratum appears in J Gastroenterol Hepatol. 2007 May;22(5):768] Exclusion Reason -Not Relevant. [PubMed: 17444850]
  187. Kunzler-Heule PPE. Hepatitis C! Experience in diagnosis and medical treatment. A literature review. Pflege. 2012 Jun;25(3):185–95. Exclusion Reason - Background. [PubMed: 22661065]
  188. Kurosaki M, Hiramatsu N, Sakamoto M, et al. Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis. Antiviral Therapy. 2012;17(1):35–43. Eexclusion Reason - Background. [PubMed: 22267467]
  189. Kwo PY. Boceprevir: A novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. Therapeutic Advances in Gastroenterology. 2012;5(3):179–188. Exclusion Reason - Background. [PMC free article: PMC3342569] [PubMed: 22570678]
  190. Kwo PY. Phase III results in Genotype 1 naïve patients: Predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver International. 2012;32(SUPPL 1):39–43. Exclusion Reason - No Original Data. [PubMed: 22212570]
  191. Kwong AD, Kauffman RS, Hurter P, et al. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotech. 2011;29(11):993–1003. Exclusion Reason -Background. [PubMed: 22068541]
  192. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49(1):22–31. Exclusion Reason -Wrong Outcome. [PubMed: 19085908]
  193. Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology. 2010 Nov;52(5):1573–80. Exclusion Reason - Wrong Population. [PubMed: 21038410]
  194. Lang, et al. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. Antiviral Therapy. 2010;15(4):599–606. Exclusion Reason -Not Relevant. [PubMed: 20587853]
  195. Lange CM, Susser S, Herrmann E, et al. HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a. Scandinavian Journal of Gastroenterology. 2011;46(11):1362–1368. Exclusion Reason -Wrong Outcomes. [PubMed: 21815864]
  196. Langlet P, D'Heygere F, Henrion J, et al. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients. Alimentary Pharmacology & Therapeutics. 2009 Aug 15;30(4):352–63. Exclusion Reason -Not Relevant. [PubMed: 19485978]
  197. Lau DT, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology. 1998;28(4):1121–1127. Exclusion reason - Wrong Drug. [PubMed: 9755252]
  198. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. Journal of Hepatology. 2008;49(2):163–169. Exclusion Reason -Wrong Outcomes. [PubMed: 18486984]
  199. Lee SS, Sherman M, Ramji A, et al. Randomised clinical trial: The efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. Alimentary Pharmacology and Therapeutics. 2012:37–47. Exclusion Reason - Wrong Population. [PubMed: 22050141]
  200. Le Lan C, Guillygomarc'H A, Danielou H, et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. Journal of Hepatology. 2012;56(2):334–340. Exclusion Reason - Background. [PubMed: 21756854]
  201. Lee LY, Tong CYW, Wong T, et al. New therapies for chronic hepatitis C infection: A systematic review of evidence from clinical trials. International Journal of Clinical Practice. 2012;66(4):342–355. Exclusion Reason - Background. [PubMed: 22420497]
  202. Lee SS, Roberts SK, Berak H, et al. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. Liver International. 2012. Exclusion Reason - Wrong Study Design. [PubMed: 22621707]
  203. Lindenburg CEA, Lambers FAE, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. European Journal of Gastroenterology & Hepatology. 2011 Jan;23(1):23–31. Exclusion Reason -Not Relevant. [PubMed: 21042221]
  204. Liu CH, Liang CC, Liu CJ, et al. Peginterferon plus ribavirin for 48 or 72 weeks in asian hepatitis C virus genotype 1 patients without rapid virologic response. Hepatology International. 2011;5(1):268. Exclusion Reason - Wrong Population.
  205. Livingston SE, Townshend-Bulson LJ, Bruden DL, et al. Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. International Journal of Circumpolar Health. 2012;71(1) Rxclusion Reason - Wrong design. [PMC free article: PMC3417585] [PubMed: 22564468]
  206. Lodato F, Azzaroli F, Brillanti S, et al. Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. Journal of Viral Hepatitis. 2005 Sep;12(5):536–42. [Erratum appears in J Viral Hepat. 2005 Nov;12(6):663] Exclusion Reason - Not Relevant. [PubMed: 16108771]
  207. Lok A. Preliminary study of two antiviral agents for hepatitis C genotype 1. The New England journal of medicine. 2012;366(3):273–5. Exclusion Reason -Wrong Outcomes. [PubMed: 22256805]
  208. Lok ASF, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005 Aug;42(2):282–92. Exclusion Reason -Wrong Population. [PubMed: 15986415]
  209. Lok ASF, Pawlotsky J-M. Viral hepatitis at a crossroad. Gastroenterology. 2012;142(6):1261–1263. Exclusion Reason - Background. [PubMed: 22537431]
  210. Louie KS, St Laurent S, Forssen UM, et al. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infectious Diseases. 2012;12 Exclusion Reason - Background. [PMC free article: PMC3342214] [PubMed: 22494445]
  211. Lurie Y, Rouzier-Panis R, Webster GJM, et al. Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection. Clinical Gastroenterology & Hepatology. 2005 Jun;3(6):610–5. Exclusion Reason -Wrong Drug. [PubMed: 15952104]
  212. Ma L-n, Chen X-y, Chen J, et al. Efficacy, influencing factors and safety of PEG-INF alpha-2a (PEG-INF-2a) in the treatment of chronic hepatitis C: analysis of 89 patients. Chinese Journal of Experimental & Clinical Virology. 2006 Jun;20(2):42–5. Exclusion Reason -Not Relevant. [PubMed: 16816861]
  213. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004 Oct 1;101(7):1616–22. Exclusion Reason -Wrong Outcomes. [PubMed: 15378504]
  214. Maruoka D, Imazeki F, Arai M, et al. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up. Journal of Viral Hepatitis. 2012;19(2):e97–e104. Exclusion Reason – Background. [PubMed: 22239532]
  215. Mauss S, Berger F, Vogel M, et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Zeitschrift fur Gastroenterologie. 2012;50(5):441–444. Exclusion Reason - Wrong population. [PubMed: 22581697]
  216. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149(6):399–403. Exclusion Reason -Wrong Drug. [PubMed: 18794559]
  217. Mangia A, Bandiera F, Montalto G, et al. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. Journal of Hepatology. 2010 Dec;53(6):1000–5. Exclusion Reason -Not Relevant. [PubMed: 20843575]
  218. Mangia A, Dalgard O, Minerva N, et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Alimentary Pharmacology & Therapeutics. 2010 Jun;31(12):1346–53. Exclusion Reason -Not Relevant. [PubMed: 20222909]
  219. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 2008 Jan;47(1):43–50. Exclusion Reason -Not Relevant. [PubMed: 18069698]
  220. Manns MP, Markova AA, Serrano BC, et al. Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver International. 2012:27–31. Exclusion Reason - Wrong Population. [PubMed: 22212568]
  221. Marcellin P, Gish RG, Gitlin N, et al. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. Journal of Hepatology. 2010 Jan;52(1):32–8. Exclusion Reason -Not Relevant. [PubMed: 19913323]
  222. Marcellin P, Jacobson IM, Zeuzem S, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin: Analyses of pre-defined subpopulations in the phase 3 advance trial. Journal of Hepatology. 2011;54:183–4. Exclusion Reason - Wrong Population.
  223. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011:459–68.e1. quiz e14. Exclusion Reason - Wrong Population. [PubMed: 21034744]
  224. Maylin S, Laouénan C, Martinot-Peignoux M, et al. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy. Journal of Clinical Virology. 2012;53(1):43–47. Exclusion Reason - Background. [PubMed: 22099210]
  225. McLaren M, Garber G, Cooper C. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Canadian Journal of Gastroenterology. 2008 Feb;22(2):133–7. Exclusion Reason -Not Relevant. [PMC free article: PMC2659131] [PubMed: 18299730]
  226. Mendez-Navarro J, Chirino RA, Corey KE, et al. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. Digestive Diseases & Sciences. 2010 Sep;55(9):2629–35. [Erratum appears in Dig Dis Sci. 2010 Oct;55(10):3010 Note: Juarez, Jesus A [added]] Exclusion Reason -Not Relevant. [PMC free article: PMC3747563] [PubMed: 19960257]
  227. Michielsen Pa, Ho E, Francque S, et al. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C? Minerva Gastroenterologica e Dietologica. 2012;58(1):65–79. Exclusion Reason - Background. [PubMed: 22419005]
  228. Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. Journal of Viral Hepatitis. 2009 Jul;16(7):479–84. Exclusion Reason -Not Relevant. [PubMed: 19215577]
  229. Milazzo L, Foschi A, Antinori S. Rapid virological response: Is it four or eight weeks? Hepatology. 2012;55(3):979. Exclusion Reason - Background. [PubMed: 22161760]
  230. Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: A powerful and flexible strategy to improve the drug delivery. Current Drug Metabolism. 2012;13(1):105–119. Exclusion Reason – Background. [PubMed: 21892917]
  231. Miller ER, McNally S, Wallace J, Schlichthorst M. The ongoing impacts of hepatitis c - a systematic narrative review of the literature. BMC Public Health. 2012;672 Exclusion Reason - Background. [PMC free article: PMC3505729] [PubMed: 22900973]
  232. Minami T, Kishikawa T, Sato M, et al. Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology. 2012:1–15. Exclusion Reason – Background. [PubMed: 22790350]
  233. Mirza S, Siddiqui AR, Hamid S, et al. Extent of liver inflammation in predicting response to interferon alpha & Ribavirin in chronic hepatitis C patients: A cohort study. BMC Gastroenterology. 2012;71 Exclusion Reason - Background. [PMC free article: PMC3502580] [PubMed: 22697612]
  234. Miyajima I. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment. Oncology Reports. 1998;5(1):201–204. Exclusion Reason - Wrong Population. [PubMed: 9458322]
  235. Mizui M, Tanaka J, Katayama K, et al. Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment: Study on 1019 carriers followed for 5–10 years. Hepatology Research. 2007;37(12):994–1001. Exclusion Reason - Wrong Drug. [PubMed: 17627620]
  236. Morishima C, Di Bisceglie AM, Rothman AL, et al. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. Journal of Viral Hepatitis. 2012;19(6):404–413. Exclusion Reason – Background. [PMC free article: PMC3349971] [PubMed: 22571902]
  237. Morishima C, Shiffman ML, Dienstag JL, et al. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. American Journal of Gastroenterology. 2012. Exclusion Reason - Background. [PMC free article: PMC3865099] [PubMed: 22688849]
  238. Moriyama M, Matsumura H, Aoki H, et al. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver International. 2005;25(1):85–90. Exclusion Reason - Wrong Drug. [PubMed: 15698403]
  239. Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54(5):1538–1546. Exclusion Reason -Wrong Outcomes. [PubMed: 22045671]
  240. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep;52(3):822–32. Exclusion Reason -Wrong Population. [PubMed: 20564352]
  241. Myers RP, Regimbeau C, Thevenot T, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews. 2009;(1) Exclusion Reason – Background. [PMC free article: PMC7061493] [PubMed: 12076394]
  242. Myers RP, Regimbeau C, Thevenot T, et al. Interferon for acute hepatitis C. Cochrane Database of Systematic Reviews. 2010;(4) Exclusion Reason - Background.
  243. Nagaki M, Shimizu M, Sugihara JI, et al. Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders. Alimentary Pharmacology & Therapeutics. 2009 Aug 15;30(4):343–51. Exclusion Reason -Not Relevant. [PubMed: 19485982]
  244. Napoli N, Giannelli G, Antonaci A, et al. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. Journal of Viral Hepatitis. 2008 Apr;15(4):300–4. Exclusion Reason -Not Relevant. [PubMed: 18307592]
  245. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. Journal of Viral Hepatitis. 2012;19(SUPPL 1):42–47. Exclusion Reason - Background. [PubMed: 22233413]
  246. Nelson DR, Benhamou Y, Chuang W-L, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon- in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology. 2010 Oct;139(4):1267–76. Exclusion Reason -Not Relevant. [PMC free article: PMC3175757] [PubMed: 20600017]
  247. Neukam K, Mira JA, Gilabert I, et al. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2012;31(6):1225–1232. Exclusion Reason - Wrong Population. [PubMed: 21971821]
  248. Neumann AU, Pianko S, Zeuzem S, et al. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naive patients with genotype 1, chronic hepatitis C. Journal of Hepatology. 2009 Jul;51(1):21–8. Exclusion Reason -Not Relevant. [PubMed: 19447518]
  249. Nevens E, Van Vlierberghe H, D'Heygere E, et al. A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naive and relapsed chronic hepatitis C patients. Acta Gastroenterologica Belgica. 2010 Apr–Jun;73(2):223–8. Exclusion Reason -Wrong Population. [PubMed: 20690560]
  250. Niederau C. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World Journal of Gastroenterology. 2012 Mar 28;18(12):1339–47. Exclusion Reason - Background. [PMC free article: PMC3319960] [PubMed: 22493547]
  251. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346(8982):1051–1055. Exclusion Reason - Wrong Drug. [PubMed: 7564784]
  252. Omata M, Kanda T, Yu M, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatology International. 2012;6(2):409–435. Exclusion Reason – Background. [PubMed: 26201405]
  253. O'Shaughnessy MM, O'Regan JA, Murray FE, et al. Re-infection following sustained virological response with a different hepatitis C virus genotype: Implications for infection control policy. CKJ: Clinical Kidney Journal. 2012;5(3):250–253. Exclusion Reason - Background. [PMC free article: PMC4400513] [PubMed: 26069778]
  254. Oze T, Hiramatsu N, Song C, et al. Reducing peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin. Journal of Gastroenterology. 2012;47(3):334–342. Exclusion Reason - Background. [PubMed: 22109353]
  255. Ozeki I, Akaike J, Karino Y, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. Journal of Gastroenterology. 2011;46(7):929–937. Exclusion Reason -Wrong Outcomes. [PubMed: 21556829]
  256. Palmer. The future of hepatitis C beyond protease inhibitors-will hepatitis C be a disease of the past? Practical Gastroenterology. 2012;36(1):13–22. Exclusion Reason – Background.
  257. Palmer M, Rubin R, Rustgi V, et al. Randomised clinical trial: Pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Alimentary Pharmacology and Therapeutics. 2012;36(4):370–378. Exclusion Reason – Background. [PMC free article: PMC3492905] [PubMed: 22708649]
  258. Papafragkakis H, Rao MS, Moehlen M, et al. Depression and pegylated interferon-based hepatitis C treatment. International Journal of Interferon, Cytokine and Mediator Research. 2012;4(1):25–35. Exclusion Reason - Background.
  259. Papastergiou V, Dimitroulopoulos D, Skorda L, et al. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter? Journal of Medical Virology. 2012;84(8):1217–1223. Exclusion Reason - Wrong Study Design. [PubMed: 22711349]
  260. Patel K, Benhamou Y, Yoshida EM, et al. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. Journal of Viral Hepatitis. 2009 Mar;16(3):178–86. Exclusion Reason -Wrong Outcome. [PubMed: 19175870]
  261. Pawelczyk T, Pawelczyk A, Strzelecki D, et al. Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. General Hospital Psychiatry. 2008 Nov–Dec;30(6):501–8. Exclusion Reason -Not Relevant. [PubMed: 19061675]
  262. Pawlotsky. The Results of Phase III Clinical Trial With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending. Gastroenterology. 2011. Exclusion Reason -Wrong Outcomes. [PubMed: 21255572]
  263. Pawlotsky. New antiviral agents for hepatitis C. F1000 Biology Reports. 2012;4(1) Exclusion Reason - Background. [PMC free article: PMC3292288] [PubMed: 22403588]
  264. Peese. HCV protease inhibitor telaprevir: phase II clinical results. Drug Discovery Today. 2010;15(9–10):406. Exclusion Reason –Background.
  265. Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED). Exclusion Reason - Wrong Population.
  266. Perry. Telaprevir: A review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 2012;72(5):619–641. Exclusion Reason - Background. [PubMed: 22439668]
  267. A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 HCV. Exclusion Reason - Wrong Population.
  268. Pockros P, Zeuzem S, Lawitz EJ, et al. Telaprevir-based regimen in genotype 1 hepatitis C virus-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results. Gastroenterology. 2011;140(5):S898. Exclusion Reason - Wrong Population.
  269. Poordad F, Lawitz E, Shiffman ML, et al. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2010 Oct;52(4):1208–15. Exclusion Reason -Not Relevant. [PubMed: 20721883]
  270. Poordad F, Bronowicki J, Gordon SC, et al. Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. Gastroenterology. 2012. Exclusion Reason - Background. [PubMed: 22626609]
  271. Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. Journal of Hepatology. 2008 Nov;49(5):688–94. Exclusion Reason -Not Relevant. [PubMed: 18490077]
  272. Powis J, Peltekian KM, Lee SS, et al. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. Journal of Viral Hepatitis. 2008 Jan;15(1):52–7. Exclusion Reason -Not Relevant. [PMC free article: PMC2229559] [PubMed: 18088245]
  273. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Journal of Viral Hepatitis. 2002 Mar;9(2):128–33. Exclusion Reason -Not Relevant. [PubMed: 11876795]
  274. Poynard T, Myers RP. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews. 2009;(1) Exclusion Reason - Background. [PubMed: 12519606]
  275. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002 May;122(5):1303–13. Exclusion Reason -Not Relevant. [PubMed: 11984517]
  276. Pradat P, Tillmann HL, Sauleda S, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. Journal of Viral Hepatitis. 2007;14(8):556–563. Exclusion Reason - Wrong Population. [PubMed: 17650289]
  277. Qu LS, Chen H, Kuai XL, et al. Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials. Hepatology Research. 2012;42(8):782–789. Exclusion Reason – Background. [PubMed: 22414050]
  278. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary Pharmacology and Therapeutics. 2012;35(6):647–662. Exclusion Reason - Background. [PubMed: 22296568]
  279. Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients. Exclusion Reason - Wrong Population.
  280. Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181). 2011. Exclusion Reason - Background.
  281. Re VL, Teal V, Localio R, et al. Adherence to hepatitis C virus therapy: Relationship with virologic outcomes and change in adherence over time. Journal of the International Association of Physicians in AIDS Care. 2011;10(3):195–6. Exclusion Reason - Wrong Population.
  282. Reddy KR, Messinger D, Popescu M, et al. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. Journal of Viral Hepatitis. 2009 Oct;16(10):724–31. Exclusion Reason -Not Relevant. [PubMed: 19486469]
  283. Reddy KR, Lin F, Zoulim F, et al. Response-guided and -unguided treatment of chronic hepatitis C. Liver International. 2012;32(SUPPL 1):64–73. Exclusion Reason – Background. [PubMed: 22212575]
  284. Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed). 2011. Exclusion Reason - Background.
  285. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010 Mar;138(3):913–21. Exclusion Reason -Wrong Outcome. [PubMed: 19852962]
  286. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006 Oct;131(4):997–1002. Exclusion Reason -Wrong Drug. [PubMed: 17030169]
  287. Roberts SK, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology. 2008 Aug;48(2):398–406. Exclusion Reason -Not Relevant. [PubMed: 18553458]
  288. Rodis JL, Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterology Nursing. 2010 Sep–Oct;33(5):368–73. Exclusion Reason -Not Relevant. [PubMed: 20890160]
  289. Rodríguez-Torres M, Burguera J, Hallman D, et al. Hepatitis C viral kinetics in Latino patients: A comparison to African American and Caucasian patients. Annals of Hepatology. 2012;11(4):450–463. Exclusion Reason - Background. [PubMed: 22700626]
  290. Roffi L, Colloredo G, Pioltelli P, et al. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antiviral Therapy. 2008;13(5):663–73. Exclusion Reason -Not Relevant. [PubMed: 18771050]
  291. Roomer R, Hansen BE, Janssen HLA, et al. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Journal of Hepatology. 2010 Sep;53(3):455–9. Exclusion Reason -Not Relevant. [PubMed: 20561709]
  292. Roomer R, Hansen BE, Janssen HLA, et al. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2010 Oct;52(4):1225–31. Exclusion Reason -Not Relevant. [PubMed: 20830784]
  293. Roomer R, Bergmann JF, Boonstra A, et al. Continuous interferon-α,2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients. Antiviral Therapy. 2012;17(3):509–517. Exclusion Reason - Background. [PubMed: 22300892]
  294. Rousseau CM, Ioannou GN, Todd-Stenberg JA, et al. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. American Journal of Public Health. 2008 May;98(5):846–52. Exclusion Reason -Not Relevant. [PMC free article: PMC2374801] [PubMed: 18382007]
  295. Rumi M, Aghemo A, Prati GM, et al. Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C. Journal of Viral Hepatitis. 2012;19(SUPPL 1):37–41. Exclusion Reason – Background. [PubMed: 22233412]
  296. Saez V, Ramón J, Peniche C, et al. Microencapsulation of alpha interferons in biodegradable microspheres. Journal of Interferon and Cytokine Research. 2012;32(7):299–311. Exclusion Reason – Background. [PubMed: 22774794]
  297. Salloum SaT, AW, et al. Treating hepatitis C infection by targeting the host. Translational Research. 2012;159(6):421–429. Exclusion Reason – Background. [PMC free article: PMC3361678] [PubMed: 22633094]
  298. Santos C, Reis A, dos Santos CV, et al. The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically. Journal of Virological Methods. 2012;179(1):17–20. Exclusion Reason - Background. [PubMed: 21871496]
  299. Sarwar S, Ryan EJ, Iqbal M, et al. Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection. Irish Journal of Medical Science. 2012;181(1):53–58. Exclusion Reason – Background. [PubMed: 22038749]
  300. Schaefer EAK, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology. 2012;142(6):1340–1350.e1. Exclusion Reason - Background. [PubMed: 22537441]
  301. Schneider MD, Sarrazin C. Hepatitis C triple therapy with boceprevir and telaprevir. Triple-Therapie der Hepatitis C mit Boceprevir und Telaprevir. 2012;30(1):23–34. Exclusion Reason – Background.
  302. Scotto G, Fazio V, Fornabaio C, et al. Peg-Interferon Alpha-2a versus Peg-Interferon Alpha-2b in Nonresponders with HCV Active Chronic Hepatitis: A Pilot Study. Journal of Interferon & Cytokine Research. 2008;28(10):623–630. Exclusion Reason -Wrong Outcome. [PubMed: 18778199]
  303. Sharvadze L, Karchava M, Bolokadze N, et al. Safety and efficacy of systematic administration of Filgrastim to prevent neutropenia and infections in patient with hepatitis C. Georgian Medical News. 2009 Oct;(175):32–5. Exclusion Reason -Not Relevant. [PubMed: 19893121]
  304. Sharvadze L, Tsertsvadze T, Gochitashvili N, et al. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. Georgian Medical News. 2006 Aug;(137):62–5. Exclusion Reason -Not Relevant. [PubMed: 16980747]
  305. Shen Y. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology. 2012;82(5):275–89. Exclusion Reason - Background. [PubMed: 22555181]
  306. Shiffman ML, Diago M, Tran A, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clinical Gastroenterology & Hepatology. 2006 May;4(5):645–52. [Erratum appears in Clin Gastroenterol Hepatol. 2006 Aug;4(8):1072] Exclusion Reason -Not Relevant. [PubMed: 16630770]
  307. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007 Jan;132(1):103–12. Exclusion Reason -Wrong Population. [PubMed: 17241864]
  308. Shiffman ML, Morishima C, Dienstag JL, et al. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009 Dec;137(6):1986–94. [Erratum appears in Gastroenterology. 2010 Mar;138(3):1215] Exclusion Reason -Wrong Drug. [PMC free article: PMC3774149] [PubMed: 19747918]
  309. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007 Aug;46(2):371–9. Exclusion Reason -Not Relevant. [PubMed: 17559152]
  310. Shiffman ML, Esteban R. Triple therapy for HCV genotype 1 infection: Telaprevir or boceprevir? Liver International. 2012;32(SUPPL 1):54–60. Exclusion Reason - Background. [PubMed: 22212573]
  311. Shindo M, Hamada K, Oda Y, et al. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology. 2001;33(5):1299–1302. Exclusion Reason - Wrong Drug. [PubMed: 11343259]
  312. Silva M, Poo JL, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Journal of Hepatology. 2006;45(2):204–213. Exclusion Reason - Wrong Outcome. [PubMed: 16780997]
  313. Simin M, Myers RP, Stimac D, et al. Pegylated interferon for acute hepatitis C. Cochrane Database of Systematic Reviews. 2009;(1) Exclusion Reason - Background.
  314. Simonetti RG, Gluud C, Pagliaro L. Interferon for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. 2009;(1) Exclusion Reason - Background.
  315. Singal AK, Anand BS. Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2010;44(8):583–587. Exclusion Reason -Wrong Drug. [PubMed: 20375729]
  316. Sinha S. A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. American Journal of Gastroenterology. 2004 October;99(10 (Suppl)):S77–8. 2004. Exclusion Reason - Wrong Drug.
  317. Sjogren MH, Sjogren R Jr, Lyons MF, et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases & Sciences. 2007 Jun;52(6):1540–7. Exclusion Reason -Not Relevant. [PubMed: 17406822]
  318. Slavenburg S, Weggelaar I, van Oijen MGH, et al. Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antiviral Therapy. 2009;14(8):1139–48. Exclusion Reason -Not Relevant. [PubMed: 20032543]
  319. Smith LS, Nelson M, Naik S, et al. Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C. The Annals of Pharmacotherapy. 2011 May 1;45(5):639–648. 2011. Exclusion Reason -Background. [PubMed: 21558488]
  320. Snoeck E, Wade JR, Duff F, et al. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. British Journal of Clinical Pharmacology. 2006 Dec;62(6):699–709. Exclusion Reason -Not Relevant. [PMC free article: PMC1885193] [PubMed: 17118125]
  321. Snow KK, Bonkovsky HL, Fontana RJ, et al. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2010 Apr;31(7):719–34. Exclusion Reason -Wrong Population. [PMC free article: PMC2923484] [PubMed: 20070284]
  322. Soga K, Shibasaki K, Aoyagi Y. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepato-Gastroenterology. 2005 Jul–Aug;52(64):1154–8. Exclusion Reason -Wrong Drug. [PubMed: 16001651]
  323. Sood A, Sobti P, Midha V, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian Journal of Gastroenterology. 2010 Mar;29(2):62–5. Exclusion Reason -Not Relevant. [PubMed: 20443101]
  324. Sporea I, Danila M, Sirli R, et al. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. Journal of Gastrointestinal & Liver Diseases. 2006 Jun;15(2):125–30. Exclusion Reason -Wrong Outcome. [PubMed: 16802006]
  325. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection. Eur J Public Health. 2009:245–53. Exclusion Reason – Wrong Design. [PubMed: 19196737]
  326. Strayer DR, Carter WA. Recombinant and natural human interferons: Analysis of the incidence and clinical impact of neutralizing antibodies. Journal of Interferon and Cytokine Research. 2012;32(3):95–102. Exclusion Reason - Background. [PubMed: 22132684]
  327. A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a 40KD ) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C. Exclusion Reason - Wrong Population.
  328. Su KP. Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications. BioMedicine (Netherlands). 2012;2(2):68–74. Exclusion Reason - Background.
  329. Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of Clinical Virology. 2011;52(4):321–327. Exclusion Reason -Not Relevant. [PubMed: 21924672]
  330. Suzuki F, Akuta N, Suzuki Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatology Research. 2009;39(11):1056–1063. Exclusion Reason -Wrong Outcomes. [PubMed: 19619256]
  331. Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2010. n-a. Exclusion Reason -Not Relevant. [PubMed: 21246582]
  332. Suzuki K, Ohkoshi S, Yano M, et al. Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. Liver International. 2003;23(3):143–147. Exclusion Reason - Wrong Population. [PubMed: 12955876]
  333. Takaki S, Kawakami Y, Imamura M, et al. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. Intervirology. 2007;50(6):439–46. Exclusion Reason -Not Relevant. [PubMed: 18253048]
  334. Tanaka K, Sata M, Uchimura Y, et al. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma? Oncol Rep. 1998;5(1):205–208. Exclusion Reason - Wrong Population. [PubMed: 9458323]
  335. Tang KH, Herrmann E, Pachiadakis I, et al. Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin. Alimentary Pharmacology & Therapeutics. 2008 May;27(9):810–9. Exclusion Reason -Not Relevant. [PubMed: 18221408]
  336. Tangkijvanich P, Komolmit P, Mahachai V, et al. Response-guided therapy for patients with hepatitis C virus genotype 6 infection: A pilot study. Journal of Viral Hepatitis. 2012;19(6):423–430. Exclusion Reason - Wrong Study Design. [PubMed: 22571904]
  337. Testino G, Ansaldi F, Andorno E, et al. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis. Hepato-Gastroenterology. 2002 Nov–Dec;49(48):1636–8. Exclusion Reason -Not Relevant. [PubMed: 12397752]
  338. Testino G, Icardi G. Hepatocellular carcinoma and interferon therapy in HCV compensated cirrhosis: evaluation in relation to virological response. Hepato-Gastroenterology. 2005 May–Jun;52(63) 4 p preceding table of contents. Exclusion Reason -Wrong Drug. [PubMed: 15966175]
  339. Thompson AJ, Clark PJ, Muir AJ, et al. Reply to "iL28B polymorphism and hepatitis C: A genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects?". Journal of Hepatology. 2012;56(3):742–743. Exclusion Reason - Background. [PubMed: 22340675]
  340. Thu Thuy PT, Bunchorntavakul C, Tan Dat H, et al. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. Journal of Hepatology. 2012;56(5):1012–1018. Exclusion Reason - Wrong Population. [PubMed: 22266603]
  341. Toyoda H, Kumada T, Kiriyama S, et al. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response. Liver International. 2009 Jan;29(1):120–5. Exclusion Reason -Not Relevant. [PubMed: 18384519]
  342. Tran HA, Attia JR, Jones TL, et al. Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. Journal of Gastroenterology & Hepatology. 2007 Apr;22(4):472–6. Exclusion Reason -Not Relevant. [PubMed: 17376035]
  343. Tran HA, Malcolm Reeves GE, Gibson R, et al. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. Journal of Gastroenterology & Hepatology. 2009 Jul;24(7):1163–8. Exclusion Reason -Not Relevant. [PubMed: 19682190]
  344. Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255). 2011. Exclusion Reason - Background.
  345. Tsubota A, Satoh K-i, Aizawa M, et al. Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study. World Journal of Gastroenterology. 2008 Dec 21;14(47):7220–4. Exclusion Reason -Not Relevant. [PMC free article: PMC2776880] [PubMed: 19084937]
  346. van Soest H, van der Schaar PJ, Koek GH, et al. No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Digestive & Liver Disease. 2010 Jul;42(7):496–502. Exclusion Reason -Not Relevant. [PubMed: 20018575]
  347. Van Vlerken LG, Huisman EJ, Van Soest H, et al. Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients. Journal of Viral Hepatitis. 2012;19(1):39–46. Exclusion Reason - Wrong design. [PubMed: 21114586]
  348. Villa E, Cammà C, Di Leo A, et al. Peginterferon-A-2B plus ribavirin is more effective than peginterferon-A-2A plus ribavirin in menopausal women with chronic hepatitis C. Journal of Viral Hepatitis. 2012;19(9):640–649. Exclusion Reason - Wrong Study Design. [PubMed: 22863268]
  349. Voelker R. Birth cohort screening may help find hepatitis C cases. JAMA - Journal of the American Medical Association. 2012;307(12):1242. Exclusion Reason - Background. [PubMed: 22453559]
  350. von Wagner M, Hofmann WP, Teuber G, et al. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology. 2008 Nov;48(5):1404–11. Exclusion Reason -Not Relevant. [PubMed: 18846541]
  351. Weiss JJ, Alcorn MC, Rabkin JG, et al. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. Journal of Hepatology. 2012;56(2):503–504. Exclusion Reason – Background. [PubMed: 21718669]
  352. Welsch C, Jesudian A, Zeuzem S, et al. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 2012;61(SUPPL 1):i36–i46. Exclusion Reason – Background. [PubMed: 22504918]
  353. Wilby K, Partovi N, Ford J, et al. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Canadian Journal of Gastroenterology. 2012;26(4):205–210. Exclusion Reason - Background. [PMC free article: PMC3354889] [PubMed: 22506260]
  354. Willson RA. Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection. Journal of Clinical Gastroenterology. 2004 Sep;38(8):717–22. Exclusion Reason -Not Relevant. [PubMed: 15319658]
  355. Witthoeft T, Hueppe D, John C, et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. Journal of Viral Hepatitis. 2010 Jul;17(7):459–68. Exclusion Reason -Not Relevant. [PubMed: 20158603]
  356. Wójciak RW, Mojs E, Kowalska J, et al. The assessment of trace elements nutritional habits in patients with HCV with or without interferon therapy. Trace Elements and Electrolytes. 2012;29(3):189–193. Exclusion Reason - Background.
  357. Wright M, Forton D, Main J, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. Journal of Viral Hepatitis. 2005 Jan;12(1):58–66. Exclusion Reason -Not Relevant. [PubMed: 15655049]
  358. Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technology Assessment (Winchester, England). 2006 Jul;10(21):1–113. 2006. Exclusion Reason -Not Relevant. [PubMed: 16750059]
  359. Xie Y, Xu D-Z, Lu Z-M, et al. Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study. Hepatobiliary & Pancreatic Diseases International. 2004 Aug;3(3):369–74. Exclusion Reason -Not Relevant. [PubMed: 15313671]
  360. Xie Y, Xu D-Z, Lu Z-M, et al. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial. Hepatobiliary & Pancreatic Diseases International. 2005 May;4(2):213–9. Exclusion Reason -Not Relevant. [PubMed: 15908318]
  361. Yabuuchi I, Imai Y, Kawata S, et al. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver. 2000;20(4):290–295. Exclusion Reason - Wrong Population. [PubMed: 10959807]
  362. Yamada I, Suzuki F, Kamiya N, et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. Journal of Viral Hepatitis. 2012;19(2):112–9. Exclusion Reason - Wrong Population. [PMC free article: PMC3584515] [PubMed: 22239508]
  363. Yoneyama K, Yamaguchi M, Kiuchi Y, et al. Analysis of Background Factors Influencing Long-Term Prognosis of Patients with Chronic Hepatitis C Treated with Interferon. Intervirology. 2002;45(1):11–19. Exclusion Reason - Wrong Drug. [PubMed: 11937766]
  364. Younossi ZM, Lawitz EJ, Krastev Z, et al. SELECT-2 clinical trial assessing the efficacy and saftey of controlled- release interferon alpha-2B (CR2b)+ribavirin (RBV) versus pegylated interferon alpha-2B (Peg2b)+RBV in treatment-NaiVE genotype-1 (G1) hepatitis C. Gastroenterology. 2011;140(5):S942. Exclusion Reason - Wrong Population.
  365. Zarski J-P, Sturm N, Desmorat H, et al. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study. Liver International. 2010 Aug;30(7):1049–58. Exclusion Reason -Wrong Population. [PubMed: 20492512]
  366. Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology. 2005 Aug;43(2):250–7. Exclusion Reason -Not Relevant. [PubMed: 16082736]
  367. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon- in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010 Oct;139(4):1257–66. Exclusion Reason -Not Relevant. [PubMed: 20600013]
  368. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2008 Aug;48(2):407–17. Exclusion Reason -Not Relevant. [PubMed: 18666223]
  369. Zhao S, Cheng D, Liu E, et al. Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients. European Journal of Clinical Microbiology & Infectious Diseases. 2008 Dec;27(12):1183–92. Exclusion Reason -Wrong Population. [PubMed: 18560911]
  370. Zhao S, Liu E, Wei K, et al. Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C. European Journal of Clinical Microbiology & Infectious Diseases. 2011 Jan;30(1):51–7. Exclusion Reason -Not Relevant. [PubMed: 20827497]
  371. Zhao SH, Chu YL, Cheng DX, et al. Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C. International Journal of Clinical Practice. 2009 Sep;63(9):1334–9. Exclusion Reason - Not Relevant. [PubMed: 19691617]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.5M)

Other titles in these collections

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...